Frontierby eninvs

Language: EN · RU

← Region

Aspen Pharmacare ZAR

Update

Sector: Pharma

ZA_APN

Price chart

156.5 ZARDay -0.32%

Key metrics

Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.

Market

Price
156.5 ZAR · -0.32%
Market cap
69.5 bn ZAR

Growth

Δ revenue y/y
-3.0%
Δ EBITDA y/y
-13.7%

Multiples

P/E (LTM)
20.9x
P/B (FY)
0.8x
P/E (ann.)
23.6x
EV/EBITDA (LTM)
4.2x
EV/EBITDA (ann.)
17.4x

Cash return

Dividend yield
1.4%
FCF yield (LTM)
-5.5%

Value creation

fundamental value/yr, % of market cap
Value created / year
-21.0%
↓ details

Liquidity

Daily turnover (listing)
56 mln ZAR

Shares: yahoo_fundamentals_timeseries/APN.JO

Amounts: USD (converted) · As reported
Converted modes use NBK / ECB-linked rates: balance sheet date for BS items, period average for P&L and cash flow (see filing row evidence). As reported keeps each row in its filing currency.

Financial dynamics

Monetary columns are in B ZAR, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.

DatePeriodStatusRevenueB ZAROperating profitB ZARD&AB ZAREBITDAB ZARNet profitB ZAROperating CFB ZARCapex + M&AB ZARAssetsB ZAREquityB ZARROE (annualized)Net debtB ZARSource
2025-12-31H1 2025 (6M)OK-26.3
y/y —
-6.8
y/y —
-1.1
y/y —
-7.9
y/y —
2.6
y/y —
-1.63.9128.0
y/y —
81.1
y/y —
3.5%27.3Link
2025-06-30FY 2025 (12M)OK43.4
y/y -3.0%
8.6
y/y -17.4%
2.1
y/y 5.9%
10.7
y/y -13.7%
-1.1
y/y -124.6%
5.2-5.1135.9
y/y -2.3%
84.9
y/y 0.0%
-1.3%29.2Link
2024-06-30FY 2024 (12M)OK44.7
y/y 9.8%
10.4
y/y 26.7%
2.0
y/y 10.3%
12.4
y/y 23.8%
4.4
y/y -15.8%
6.2-5.5139.1
y/y 3.6%
84.9
y/y -1.6%
5.1%23.5Link
2023-06-30FY 2023 (12M)OK40.7
y/y —
8.2
y/y —
1.8
y/y —
10.0
y/y —
5.2
y/y —
5.5-3.2134.3
y/y —
86.2
y/y —
—18.2Link
Data quality No obvious scale, balance-sheet, or cash-flow sanity issues in the displayed periods.

Revenue & EBITDA

RevenueEBITDA

Quarterly values (ZAR mln)

010 00020 00030 00040 0002023 FY2024 FY2025 FY

Year-over-year change

-20%-10%0%10%20%2023 FY2024 FY2025 FY

Cash flow

FCF (ZAR mln)

-4 000-2 00002 0002023 FY2024 FY2025 FY

Net debt / cash (ZAR mln)

010 00020 00030 0002023 H12023 FY2024 H12024 FY2025 H12025 FY

Revenue growth & acceleration

Growth decelerating ▼
Last-year revenue growth -3% vs +10% the year before — a -12.8 pp move. 3-year CAGR +4%.
revenue growth by year: 2023 +5% · 2024 +10% · 2025 -3%
The growth-acceleration signal behind the GARP+acceleration strategy — it favours companies whose revenue growth is speeding up and flags those slowing down (the second derivative of growth).

Fundamental value creation

Value the company creates per year, as a % of market cap

Value created per year: -20.8%

How this was calculated
1. EBITDA growth (latest quarter YoY, annualised)
[EBITDA latest qtr − EBITDA year-ago qtr] × annualisation X
= —
-1 705
2. Current EV/EBITDA (LTM)
(Market cap + Net debt) ÷ EBITDA (LTM)
= (69 490 + 27 323) ÷ 10 714
9.0x
3. Target multiple
(Current EV/EBITDA + 8) ÷ 2
= (9.0 + 8) ÷ 2
8.5x
4. Cash flow (balance method, LTM)
Net-debt reduction + dividends + buybacks − equity issuance
= -3 801 + 0 + 0 − 0
104
5. Value created per year
(EBITDA growth × Target multiple + Cash flow − Dilution) ÷ Market cap
= (-1 705 × 8.5 + 104) ÷ 69 490
-20.8%

Amounts in millions of the reporting currency. EBITDA growth is the latest quarter vs the same quarter a year ago, annualised.

Caveats:

Dividends

Paid (completed)

DatePer shareDetailsStatusSource
2025-10-01211 ZAREx-dividend: 211 ZAR per sharePaidYahoo Finance (ex-div)
2024-09-18359 ZAREx-dividend: 359 ZAR per sharePaidYahoo Finance (ex-div)
2023-09-20342 ZAREx-dividend: 342 ZAR per sharePaidYahoo Finance (ex-div)
2022-09-21326 ZAREx-dividend: 326 ZAR per sharePaidYahoo Finance (ex-div)
2021-09-21262 ZAREx-dividend: 262 ZAR per sharePaidYahoo Finance (ex-div)

KASE: status follows wording in the news headline (paid vs intends to pay). Yahoo: amounts are cash dividends per share on ex-dividend dates (UTC calendar date). stockscope.uz (UZ): amounts are per share in UZS by publication date (not necessarily ex-div).

Investor reporting (IR): https://www.aspenpharma.com/investor-relations/

Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)